Literature DB >> 17038873

Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry.

Olof Beck1, Inger Ohman, Helena K Nordgren.   

Abstract

A method based on electrospray ionization liquid chromatography-mass spectrometry was developed for the quantitative determination of lamotrigine and three of its reported metabolites, lamotrigine-2-N-glucuronide, lamotrigine-2-N-methyl, and lamotrigine-2-N-oxide in human blood plasma. The method utilized sample preparation by precipitation of proteins with acetonitrile, chromatographic separation on a reversed-phase system by gradient elution, and monitoring of the protonated molecular ions. Two internal standards, 3,5-diamino-6-(2-methoxyphenyl)-1,2,4-triazine and morphine-3-glucuronide-D3, were utilized to achieve precise quantification. The method validation comprised a demonstration of an agreement in the quantification of lamotrigine with that of a routine HPLC-UV method. The limits of detection were between 0.05 and 0.16 micromol/L. The method was employed for the measurement of clinical samples collected from 55 patients in steady-state prior to the dose intake (trough level). Lamotrigine and the 2-N-glucuronide were typically detected, while the N-methyl and N-oxide metabolites were detected only rarely. The median lamotrigine plasma level was 24.0 micromol/L (range, 4.3 to 64 micromol/L), the median 2-N-glucuronide level was 2.4 micromol/L (range, <0.05 to 24 micromol/L), and the median lamotrigine 2-N-glucuronide/lamotrigine ratio was 0.11 (range, <0.01 to 0.64). In conclusion, this liquid chromatographic-mass spectrometric method is suitable for simultaneous determination of lamotrigine and its metabolites in human plasma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038873     DOI: 10.1097/01.ftd.0000245779.64080.30

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

1.  Determination of lamotrigine in human serum by high-performance liquid chromatography–tandem mass spectrometry.

Authors:  Woonhyoung Lee; Jeong-Ho Kim; Hyon-Suk Kim; Oh Hun Kwon; Byung In Lee; Kyoung Heo
Journal:  Neurol Sci       Date:  2010-12       Impact factor: 3.307

2.  Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications.

Authors:  Matthew D Krasowski
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-11

3.  Validated spectrofluorimetric method for the determination of lamotrigine in tablets and human plasma through derivatization with o-phthalaldehyde.

Authors:  Nahed M El-Enany; Dina T El-Sherbiny; Amina A Abdelal; Fathalla F Belal
Journal:  J Fluoresc       Date:  2009-11-27       Impact factor: 2.217

4.  Liquid chromatography tandem mass spectrometry method for the estimation of lamotrigine in human plasma: Application to a pharmacokinetic study.

Authors:  Santosh Ghatol; Vatsal Vithlani; Sanjay Gurule; Arshad Khuroo; Tausif Monif; Pankaj Partani
Journal:  J Pharm Anal       Date:  2012-09-28

5.  Hyperpolarization-Activated Cyclic Nucleotide-Gated Non-selective (HCN) Ion Channels Regulate Human and Murine Urinary Bladder Contractility.

Authors:  Felix Mader; Steffen Müller; Ludwig Krause; Armin Springer; Karoline Kernig; Chris Protzel; Katrin Porath; Simone Rackow; Tristan Wittstock; Marcus Frank; Oliver W Hakenberg; Rüdiger Köhling; Timo Kirschstein
Journal:  Front Physiol       Date:  2018-06-19       Impact factor: 4.566

6.  Correlation of elevated lamotrigine and levetiracetam serum/plasma levels with toxicity: A long-term retrospective review at an academic medical center.

Authors:  Kelly E Wood; Kendra L Palmer; Matthew D Krasowski
Journal:  Toxicol Rep       Date:  2021-08-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.